Skip to main content

Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009–2010

American Journal of Cardiovascular Drugs volume 17, pages 243–249 (2017)Cite this article

Abstract

Purpose

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain, inflammation, and fever in the USA. Unfortunately, NSAIDs have been associated with an increased risk of adverse cardiovascular events, especially among NSAID users with established cardiovascular disease (CVD). In 2005, the Food and Drug Administration (FDA) released an initial warning regarding NSAID use and CVD risk, and recently, in July 2015, released an updated statement strengthening this initial warning. The purpose of this study is to evaluate the rates of NSAID use among patients with CVD following the 2005 FDA warning regarding NSAID use and increased CVD risk.

Methods

This was a retrospective, cross-sectional study of participants from the National Health and Nutrition Examination Survey, 2009–2010. Participants’ CVD status was determined by self-reported diagnosis. Current use of over the counter (OTC) NSAIDs was defined by self-reported use of ibuprofen or naproxen, and we identified the current use of prescription NSAIDs in the database of prescription medication.

Results

Respondents with CVD were 2.1 times more likely to use OTC NSAIDs or prescription NSAIDs than respondents without CVD. Among CVD patients, respondents with angina and myocardial infarction were 60% more likely to use any form of NSAID, and respondents with congestive heart failure were less likely to use any form of NSAID than those with other forms of CVD.

Conclusions

Our results indicate that there is still a large proportion of CVD patients using NSAIDs. It is now crucial to determine the reasons why prescribers are still prescribing NSAIDs despite the FDA warning.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abbreviations

CVD:

Cardiovascular disease

CDC:

Centers for Disease Control and Prevention

CAD:

Coronary artery disease

CHF:

Congestive heart failure

COX:

Cyclo-oxygenase

FDA:

Food and Drug Administration

MI:

Myocardial infarction

NHANES:

National Health and Nutrition Examination Survey

NSAIDs:

Nonsteroidal anti-inflammatory drugs

OTC:

Over-the-counter

References

  1. Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf. 2003;12(4):315–26. doi:10.1002/pds.755.

    Article  PubMed  Google Scholar 

  2. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165(2):189–92. doi:10.1001/archinte.165.2.189.

    CAS  Article  PubMed  Google Scholar 

  3. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet (London, England). 2005;365(9458):475–81. doi:10.1016/s0140-6736(05)17864-7.

    CAS  Article  Google Scholar 

  4. Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med. 2008;168(11):1219–24. doi:10.1001/archinte.168.11.1219.

    Article  PubMed  Google Scholar 

  5. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27(14):1657–63. doi:10.1093/eurheartj/ehl053.

    Article  PubMed  Google Scholar 

  6. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case–control study. Arch Intern Med. 2005;165(9):978–84. doi:10.1001/archinte.165.9.978.

    CAS  Article  PubMed  Google Scholar 

  7. Lamberts M, Lip GY, Hansen ML, Lindhardsen J, Olesen JB, Raunso J, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med. 2014;161(10):690–8. doi:10.7326/m13-1581.

    Article  PubMed  Google Scholar 

  8. Rabinovitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 1992;87(12):1696–704.

    CAS  PubMed  Google Scholar 

  9. Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbol E, Sorensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. Jama. 2015;313(8):805–14. doi:10.1001/jama.2015.0809.

    CAS  Article  PubMed  Google Scholar 

  10. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (Clinical Research ed). 2011;342:c7086. doi:10.1136/bmj.c7086.

    Article  PubMed Central  Google Scholar 

  11. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5b):13s–24s.

    CAS  Article  PubMed  Google Scholar 

  12. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141–9. doi:10.1001/archinternmed.2008.525.

    CAS  Article  PubMed  Google Scholar 

  13. Kohli P, Steg PG, Cannon CP, Smith SC Jr, Eagle KA, Ohman EM, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014;127(1):53–60.e1. doi:10.1016/j.amjmed.2013.08.017.

    CAS  Article  PubMed  Google Scholar 

  14. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155–63. doi:10.1161/circoutcomes.108.805689.

    Article  PubMed  Google Scholar 

  15. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226–35. doi:10.1161/circulationaha.110.004671.

    CAS  Article  PubMed  Google Scholar 

  16. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–42. doi:10.1161/circulationaha.106.181424.

    Article  PubMed  Google Scholar 

  17. Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (London, England). 2008;371(9608):270–3. doi:10.1016/s0140-6736(08)60137-3.

    CAS  Article  Google Scholar 

  18. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45(8):1295–301. doi:10.1016/j.jacc.2005.01.045.

    CAS  Article  PubMed  Google Scholar 

  19. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–17. doi:10.1056/NEJMoa003199.

    CAS  Article  PubMed  Google Scholar 

  20. Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis. 2007;66(6):764–70. doi:10.1136/ard.2006.066001.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–83. doi:10.1056/NEJMra052717.

    CAS  Article  PubMed  Google Scholar 

  22. Pirlamarla P, Bond RM. FDA labeling of NSAIDs: review of nonsteroidal anti-inflammatory drugs in cardiovascular disease. Trends Cardiovasc Med. 2016;. doi:10.1016/j.tcm.2016.04.011.

    PubMed  Google Scholar 

  23. Davidoff AJ, Miller GE, Sarpong EM, Yang E, Brandt N, Fick DM. Prevalence of potentially inappropriate medication use in older adults using the 2012 Beers criteria. J Am Geriatr Soc. 2015;63(3):486–500. doi:10.1111/jgs.13320.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The project described was partially supported by the National Institute of General Medical Sciences, U54GM104942. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH).

Author information

Affiliations

  1. School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA

    Gregory Castelli

  2. Department of Family Medicine, West Virginia University, Morgantown, WV, 26506, USA

    Gregory Castelli, Ashley Petrone, Jun Xiang, Carl Shrader & Dana King

Authors
  1. Gregory Castelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashley Petrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carl Shrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dana King
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashley Petrone.

Ethics declarations

This was a retrospective analysis of publicly available de-identified data; therefore, no institutional review board approval was warranted for this study.

Conflict of interest

All authors—Gregory Castelli, Ashley Petrone, Jun Xiang, Carl Shrader, and Dana King—declare that they have no conflict of interest that might be relevant to the contents of this article.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Castelli, G., Petrone, A., Xiang, J. et al. Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009–2010. Am J Cardiovasc Drugs 17, 243–249 (2017). https://doi.org/10.1007/s40256-016-0212-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-016-0212-1

Keywords

  • Prescription Nsaid
  • Inappropriate Medication Prescription
  • Total Nsaid
  • Platelet Binding Site